Retrospective analysis of neonatal data in a monocentric cohort of 170 newborns of polydrug-using mothers, île-de-France, 1999-2008;Analyse rétrospective des données de 170 nouveau-nés de mères consommatrices de substances psychoactives

Archives de Pediatrie

Volumn 20, Issue 2, 2013, Pages 146-155

  Lejeune, C ^a   Genest, L ^b   Miossec, E ^a   Simonpoli, A M ^c   Simmat Durand, L ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b EHESS Sciences   (France)

^c HÔPITAL LOUIS MOURIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMPHETAMINE; BENZODIAZEPINE; CANNABIS; COCAINE; DIAMORPHINE; MORPHINE; OPIATE; PSYCHOTROPIC AGENT;

ABORTION; ADULT; ALCOHOLISM; ARTICLE; BIRTH WEIGHT; BODY HEIGHT; BREAST FEEDING; COHORT ANALYSIS; CORRELATION ANALYSIS; DEMOGRAPHY; FEMALE; FETAL ALCOHOL SYNDROME; FOSTER CARE; FRANCE; GESTATIONAL AGE; HEAD CIRCUMFERENCE; HOSPITAL DISCHARGE; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL BEHAVIOR; MEDICAL DECISION MAKING; MOTHER CHILD RELATION; MULTIPLE DRUG ABUSE; NEWBORN; NEWBORN CARE; NEWBORN MORBIDITY; PERINATAL DRUG EXPOSURE; PREGNANCY; PREMATURITY; PRENATAL CARE; PRIMIPARA; RETROSPECTIVE STUDY; SOCIAL ASPECT; SOCIAL STATUS; SPONTANEOUS ABORTION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ADULT; FEMALE; FRANCE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS; RETROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS;

EID: 84873209528     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/j.arcped.2012.11.014     Document Type: Article

References (32)

1. Jacobson J.L., Jacobson S.W., Sokol R.J., et al. Effects of alcohol use, smoking, and illicit drug use on fetal growth in black infants. J Pediatr 1994, 124:757-764.
2. Brulet C., Chanal C., Ravel P., et al. Un suivi multidisciplinaire et un soutien psychosocial diminuent les complications de la dépendance aux opiacés chez les femmes enceintes : 114 grossesses suivies en 5ans. Presse Med 2007, 36:1571-1580.
3. Lejeune C. évolution des modalités de prise en charge des femmes enceintes toxicomanes et de leurs enfants. Arch Pediatr 2000, 7(Suppl. 2):283-284.
4. Lejeune C., Simmat-Durand L., Gourarier L., et al. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. Drug Alcohol Depend 2006, 82:250-257.
5. Mayet S., Groshkova T., Morgan L., et al. Drugs, alcohol and pregnant women - changing characteristics of women engaging with a specialist perinatal outreach addictions service. Drug Alcohol Rev 2008, 27:490-496.
6. Mazurier E., Chanal C., Misraoui M. De la femme à l'enfant, les liens interprofessionnels autour de la femme enceinte toxicomane. Arch Pediatr 2000, 7(Suppl. 2):281-282.
7. Reicher M., Weil M., Lang J.P. Prendre en soin une femme enceinte usagère de substances psycho-actives en Alsace : le réseau maternité et addictions. Psychotropes 2010, 16:33-46.
8. Lowenstein W., Gourarier L., Coppel A., et al. La méthadone et les produits de substitution. Suivi du toxicomane par le médecin généraliste 1995, Doin, Paris.
9. Simmat-Durand L., Toutain S., Vellut N., et al. Analyse des données maternelles et obstétricales dans une cohorte rétrospective de 170 nouveau-né de mères polyconsommatrices, île-de-France, 1999-2008. J Gynécol Obstet Biol Reprod 2010, 39:649-655.
10. La santé périnatale en 2002-2003. évaluation des pratiques médicales 2004, Audipog (Association des Utilisateurs de dossiers informatisés en Pédiatrie Obstétrique et Gynécologie), Coordination Inserm, Lyon, [audipog.inserm.fr].
11. Lipstiz P.J. A proposed narcotic withdrawal score for use with newborn infants: a pragmatic evaluation of its efficacy. Clin Pediatr 1975, 14:592-594.
12. Simmat-Durand L., Miossec E., Toutain S., et al. Grossesse et polyconsommations de substances psychoactives: modifications de la clientèle et des prises en charge, 1999-2008. Sante Publique 2011, 3:231-246.
13. Abrahams R.R., Kelly S.A., Payne S., et al. Rooming-in compared with standard care for newborns of mothers using methadone or heroin. Can Fam Physician 2007, 53:1722-1730.
14. Wouldes T.A., Woodward L.J. Maternal methadone dose during pregnancy and infant clinical outcome. Neuro Toxicol Teratol 2010, 32:406-413.
15. Dryden C., Young D., Hepburn M., et al. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for health care ressource. Brit J Obstet Gynaecol 2009, 116:665-671.
16. Seligman N.S., Salva N., Hayes E.J., et al. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol 2008, 199:396.e1-396.e7.
17. Bakstad B., Sarfi M., Welle-Strand G.K., et al. Opioid maintenance treatment during pregnancy: occurrence and severity of Neonatal Abstinence Syndrome. Eur Addict Res 2009, 15:128-134.
18. Choo R.E., Huestis M.A., Schroeder J.R., et al. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004, 75:253-260.
19. Cleary B., Donnelly J., Strawbridge J. Methadone dose and neonatal abstinence syndrome - systematic review and meta-analysis. Addiction 2010, 105:2071-2084.
20. McCarthy J.J., Leamon M.H., Parr M.S., et al. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol 2005, 193:606-610.
21. Seligman N.S., Almario C.V., Hayes E.J., et al. Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. J Pediatr 2010, 157:428-433.
22. Isemann B., Meinzen-Derr J., Akinbi H. Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome. J Perinatol 2011, 31:25-29.
23. Jones H.E., Kaltenbach K., Heil S.H., et al. Neonatal Abstinence Syndrome after methadone or buprenorphine exposure. N Engl J Med 2010, 363:2320-2331.
24. Swift R., Duley M., De Petrillo P., et al. Altered methadone pharmacokinetics in pregnancy: implications for dosing. J Subst Abuse 1989, 1:453-460.
25. Saiki T., Lee S., Hannam S., et al. Neonatal abstinence syndrome - postnatal ward versus neonatal unit management. Eur J Pediatr 2010, 169:95-98.
26. Abdel-Latif M.E., Pinner J., Clews S. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 2006, 117:1163-1169.
27. Lim S., Prasad M., Samuels P. High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol 2008, 200:70.e1-70.e5.
28. Zimmermann-Baer U., Notzli U., Rentsch K., et al. Finnegan neonatal abstinence scoring system: normal values for first 3days and weeks 5-6 in no-addicted infants. Addiction 2010, 105:524-528.
29. Osborn D.A., Cole M., Jeffery H. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2010, 10. [CD002059].
30. Osborn D.A., Jeffery H., Cole M. Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2010, 10. [CD002053].
31. Miles J., Sugumar K., Sims D., et al. Methadone-exposed newborn infants: outcome after alterations to a service for mothers and infants. Child Care Health Dev 2006, 33:206-212.
32. Arlettaz R., Kashiwagi M., Das-Kundu S., et al. Methadone maintenane program in a Swiss perinatal center. (II): neonatal outcome and social ressources. Acta Obstet Gynecol Scand 2005, 84:145-150.